Peutz-Jeghers Syndrome
15
3
4
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
6.7%
1 terminated out of 15 trials
80.0%
-6.5% vs benchmark
13%
2 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (15)
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex
Familial Investigations of Childhood Cancer Predisposition
The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
Celecoxib for Prevention of Progression in Peutz-Jeghers Syndrome
Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome
Poorly Differentiated Adenocarcinoma of the Jejunum in a Patient With Peutz-Jeghers Syndrome: A Case Report
Inherited Cancer Early Diagnosis (ICED) Study
Cold Snare Polypectomy for Small Bowel Polyps in Patients With Peutz-Jeghers Syndrome
Registry of Subjects at Risk of Pancreatic Cancer
Cancer of the Pancreas Screening Study (CAPS 3)
Pancreatic Cancer Screening of High-Risk Individuals in Arkansas
Efficacy of Rapamycin (Sirolimus) in the Treatment of Peutz-Jeghers Syndrome
Study of Accurate Diagnosis and Treatment of Peutz-Jeghers Syndrome
Hereditary Colorectal and Associated Tumor Registry Study
Study of Everolimus in the Treatment of Advanced Malignancies in Patients With Peutz-Jeghers Syndrome